Management and treatment of chronic hepatitis B virus : Belgian Association for the Study of the Liver (BASL) 2007 guidelines
| Journal | Volume 70 - 2007 |
| Issue | Fasc.4 - Case series |
| Author(s) | I. Colle, M. Adler, R. Brenard, J. Henrion, P. Langlet, P. Michielsen, H. Orlent, H. Reynaert, D. Sprengers, P. Stärkel, P. Van Damme, C. Verslype, J. Delwaide |
| Full article |
 VIEW FREE PDF |
| (1) Department of Hepatology and Gastroenterology, Ghent University Hospital, Ghent ; (2) Department of Hepatology and Gastroenterology, Hôpital Erasme, Université Libre de Bruxelles (ULB), Brussels ; (3) Department of Hepatology and Gastroenterology, Hôpital St-Joseph, Gilly ; (4) Department of Hepatogastroenterology, Hôpital de Jolimont, Haine-Saint-Paul ; (5) Department of Hepatology and Gastroenterology, CHU Brugmann, Brussels ; (6) Department of Hepatology and Gastroenterology, University Hospital Antwerp, Edegem ; (7) Department of Hepatology and Gastroenterology, AZ-St Jan, Brugge ; (8) Department of Hepatology and Gastroenterology, UZ Brussel, Jette (Brussels) ; (9) Department of Hepatology and Gastroenterology, St-Augustinusziekenhuis, Wilrijk-Antwerpen ; (10) Department of Hepatology and Gastroenterology, Cliniques Universitaires St. Luc, Brussels ; (11) Center for evaluation of vaccination, University of Antwerp, Campus 3 Eiken, Antwerp ; (12) Department of Hepatology and Gastroenterology, University Hospital Leuven ; (13) Department of Hepatology and Gastroenterology, Centre Hospitalier Universitaire CHU Sart Tilman, Université de Liège, Liège, Belgium. |
|
Chronic hepatitis B virus (HBV) infection currently affects about 400 million people and is responsible for 500,000 to 1,000,000 deaths annually worldwide from cirrhosis and hepatocellular carcinoma (HCC) (1). For this reason, screening high risk populations to identify HBV infected persons is important so that guidelines for treatment and prevention of transmission can be given in this specific group. Recently, new drugs became available for HBV and new insights in resistance and definitions came up. SO. the purpose of this paper is providing an update of the recent literature and guidelines concerning 1. screening for chronic hepatitis B (CHB) 2. management of patients with CHB 3. treatment of CHB in mono-infected patients and in special patient populations (co-infected, transplanted and immunosuppressed patients). The recommendations are based on published infor- mation and the level of evidence is reported with each recommendation. The level of evidence is graded as : grade I : randomized controlled trials ; grade II-1 : con- trolled trials without randomization ; grade II-2 : cohort or case-control analytic study ; grade II-3 : multiple time series, dramatic uncontrolled experiments ; grade III : descriptive epidemiology, expert opinions. |
|
© Acta Gastro-Enterologica Belgica. PMID 18330099 |
